AUS
NZ
UK
CA
USA
IND
Highlights
Three ASX-listed penny stocks with market capitalisations above A$200 million
Companies span sectors including lithium, technology, and biopharmaceuticals
Share prices remain under one dollar despite large valuations
On the Australian Securities Exchange ASX Index several companies maintain penny stock pricing while operating with valuations above million. These entities are positioned across diverse sectors such as resources, technology, and healthcare. While their share prices remain below one dollar, their operations are backed by substantial market capitalisations, positioning them as key players within their respective industries.
Patriot Battery Metals (ASX:PMT) in lithium exploration
Patriot Battery Metals (ASX:PMT) is active in the lithium exploration space. The company holds assets in regions with known lithium-bearing pegmatites, with a focus on critical minerals for battery production. Its projects include large land packages with ongoing drilling programs and development planning. The company’s activities are aligned with the broader electrification and energy storage trends.
Weebit Nano (ASX:WBT) focuses on memory technology
Weebit Nano (ASX:WBT) operates within the semiconductor sector, specialising in memory technologies for integration into electronic systems. The company has developed a proprietary non-volatile memory platform and works with semiconductor foundries to advance commercial implementation. Its ReRAM technology is designed for use in embedded systems across various electronic devices.
Botanix Pharmaceuticals (ASX:BOT) targets dermatology treatments
Botanix Pharmaceuticals (ASX:BOT) is engaged in developing dermatology products using synthetic cannabidiol formulations. The company’s pipeline includes treatments aimed at skin conditions through topical delivery systems. Its lead programs have progressed through clinical stages, and the company continues to refine its product development and regulatory engagement strategies across key markets.
Market caps reflect institutional interest and capital inflow
Despite being classified as penny stocks due to their per-share pricing, each of these companies has secured a valuation above the A$200 million mark. This is often due to asset portfolios, technology platforms, or clinical pipelines that have attracted institutional capital and public market attention. These valuations reflect the scope of operations and industry relevance across resource extraction, semiconductor innovation, and biopharmaceutical development.
Penny pricing with large-scale operations
Share price alone does not define the operational scale of these ASX-listed entities. Their activities encompass international collaborations, multi-year development pipelines, and sector-specific infrastructure. The disconnect between share price and market capitalisation places these companies in a unique category on the ASX, where traditional penny stock definitions may not fully reflect their business scope.
